Ocuphire Pharma has been granted a patent for aqueous ophthalmic solutions containing phentolamine to enhance visual performance. The solution includes specific ingredients and pH levels, offering potential benefits for patients. GlobalData’s report on Ocuphire Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ocuphire Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ocuphire Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Ocuphire Pharma's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Ophthalmic solution for improving visual performance

Source: United States Patent and Trademark Office (USPTO). Credit: Ocuphire Pharma Inc

A recently granted patent (Publication Number: US11844858B2) discloses an aqueous ophthalmic solution containing 1% of phentolamine or its salt, 1% to 6% of a polyol compound with a molecular weight less than 250 g/mol, a buffer in the range of 0.1 mM to 10 mM, water, and optionally alkali metal halides. The solution is characterized by a pH between 4.0 to 7.5. Specific embodiments include the use of mannitol as the polyol compound and sodium acetate as the buffer, with the pH falling within the range of 4.5 to 6.0.

Furthermore, the patent claims another aqueous ophthalmic solution comprising 1% phentolamine mesylate, 1% to 6% mannitol, a buffer in the range of 0.1 mM to 10 mM, water, and optionally alkali metal halides. This solution also maintains a pH between 4.5 to 6.0, with specific concentrations of mannitol at 4% and the buffer at 3 mM. The inclusion of sodium acetate as the buffer component is highlighted in several claims. Additionally, the patent specifies that less than 2% of the phentolamine mesylate should degrade after storage at 25°C for 24 weeks, ensuring the stability of the solution over time.

To know more about GlobalData’s detailed insights on Ocuphire Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies